A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb
CRISPR Therapeutics
Dragonfly Therapeutics
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Incyte Corporation
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Mural Oncology, Inc
University of California, Davis
University of Colorado, Denver
Sarcoma Oncology Research Center, LLC
University Hospital, Antwerp
M.D. Anderson Cancer Center
X4 Pharmaceuticals
GlaxoSmithKline
Pharmacyclics LLC.
HUYABIO International, LLC.
Ludwig Institute for Cancer Research
Peter MacCallum Cancer Centre, Australia
Klus Pharma Inc.
Nykode Therapeutics ASA
Nektar Therapeutics
Ludwig Institute for Cancer Research
Incyte Corporation
Big Ten Cancer Research Consortium
Merck Sharp & Dohme LLC
Hoosier Cancer Research Network
Genocea Biosciences, Inc.
Incyte Corporation
National Cancer Institute (NCI)
AVEO Pharmaceuticals, Inc.
Gilead Sciences
University of Michigan Rogel Cancer Center
MedImmune LLC
National Cancer Institute (NCI)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Incyte Corporation
Eli Lilly and Company
Mirror Biologics, Inc.
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Pittsburgh
Fred Hutchinson Cancer Center
Celldex Therapeutics
Stanford University
Fuda Cancer Hospital, Guangzhou
Fred Hutchinson Cancer Center
Eisai Inc.
Mologen AG